Mustargen and Paraplatin NovaPlus
Determining the interaction of Mustargen and Paraplatin NovaPlus and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using CARBOplatin together with mechlorethamine or other chemotherapy drugs may increase the risk of side effects, especially those that affect the bone marrow or gastrointestinal tract. You may experience a greater number or more severe side effects such as nausea; vomiting; diarrhea; loss of appetite; mouth sores; abdominal pain; delayed wound healing; and impaired bone marrow function resulting in low numbers of different types of blood cells. You may also be more likely to develop anemia, bleeding problems, or infections due to low blood cell counts. You should seek medical attention if you develop paleness, fatigue, dizziness, fainting, unusual bruising or bleeding, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. You may need a dose adjustment or more frequent monitoring by your doctor to safely use these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.
MANAGEMENT: Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.
- "Product Information. Ellence (epirubicin)" Pharmacia and Upjohn, Kalamazoo, MI.
- Agencia EspaƱola de Medicamentos y Productos Sanitarios Healthcare "Centro de informaciĆ³n online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):
- "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
- "Product Information. Fluorouracil injection (fluorouracil)." Roche Laboratories, Nutley, NJ.
- EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."
- "Product Information. Zanosar (streptozocin)." Pharmacia and Upjohn, Kalamazoo, MI.
- "Product Information. Paraplatin (carboplatin)." Bristol-Myers Squibb, Princeton, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: carboplatin
Brand name: Paraplatin, CARBOplatin Novaplus
Synonyms: Paraplatin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Mustargen-Parathyroid hormone
- Mustargen-Parathyroid hormone Subcutaneous
- Mustargen-Parcopa
- Mustargen-Paregoric
- Mustargen-Paremyd
- Mustargen-Paremyd Ophthalmic
- Paraplatin NovaPlus-Mutamycin
- Paraplatin NovaPlus-Mvasi
- Paraplatin NovaPlus-Mvasi Intravenous
- Paraplatin NovaPlus-MVC-Fluoride
- Paraplatin NovaPlus-My Choice
- Paraplatin NovaPlus-My Way